Smitty, I can see your valuation on GBM or brain cancers alone, but I do believe the tumor agnostic label will be applied if the company isn't bought out too soon. If that designation is achieved, I think the decimal point could move one or two places to the right.
I'd much prefer partnering with a BP than having NWBO bought out by them. A few billion dollars for a small percentage of the company would be far more preferrable to me than a buyout. A BP with say 20% or more of the stock would gain one or more seats on the board and have a very big influence on the direction the company takes. The money such a partnership would provide should easily cover the new trials, new product development, and other needs as the company's sales revenue is growing. Such a partnership would essentially raise the share price to the price the BP was paying for their percentage of the company.
Gary
Bullish